Photo taken from mdanderson.org
Aug 9, 2024, 02:31
E2-RADIatE Oligo Care cohort, largest prospective registry cohort on oligometastatic disease – EORTC
EORTC shared a post on LinkedIn:
“We are excited to share a new publication about the E2-RADIatE Oligo Care cohort, the largest prospective registry cohort on oligometastatic disease.
This interim analysis of approximately 1600 oligometastatic patients aimed to evaluate acute toxicity within 6 months following stereotactic body radiotherapy (SBRT).
Toxicity within 6 months was low, confirming that SBRT is safe to use in the oligometastatic setting.”
Source: EORTC/LinkedIn